Previously, it has been demonstrated that TRPV2 expression correlates with worse OS and PFS for triple negative breast cancer [13], esophageal squamous cell carcinoma [46], MM [47] and gastric cancer [48]. Here, TRPV2 is linked to Miyoshi myopathy.